NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia's clobetasol propionate ophthalmic suspension 0.05% ("Clobetasol"), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel. Eyenovia will market NovaBay's prescription Avenova Antimicrobial Lid & Lash Solution through its Mydcombi and Clobetasol sales representatives strategically located across the U.S.
加利福尼亞州埃默裏維爾和紐約，2024年3月13日（GLOBE NEWSWIRE）——NovaBay Pharmicals, Inc.（紐約證券交易所美國股票代碼：NBY）和Eyenovia, Inc.（納斯達克股票代碼：EYEN）宣佈簽署一項聯合促銷協議，向美國各地的眼科護理專業人員商業化處方眼科產品。根據該協議，NovaBay將銷售Eyenovia的丙酸氯倍他索眼藥 0.05% 的懸浮液（“Clobetasol”），一種用於治療眼科手術後炎症和疼痛的類固醇，通過其美國醫生分配的渠道。Eyenovia將通過其戰略性地分佈在美國各地的Mydcombi和Clobetasol銷售代表推銷NovaBay的處方Avenova抗菌Lid & Lash Solution。
Clobetasol propionate ophthalmic suspension 0.05%, developed by Formosa Pharmaceuticals, was granted U.S. Food and Drug Administration (FDA) approval on March 4, 2024, based on clinical results showing nearly nine out of ten patients achieving complete absence of post-surgical pain and six out of ten achieving total absence of inflammation within 15 days post-ocular surgery. Eyenovia acquired the U.S. commercial rights to clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals in August 2023. Clobetasol propionate ophthalmic suspension 0.05% is expected to receive a tradename as soon as this summer.
由臺塑製藥開發的0.05％丙酸氯倍他索眼用混懸液於2024年3月4日獲得美國食品藥品監督管理局（FDA）的批准，其依據是臨床結果顯示，近十分之九的患者完全沒有術後疼痛，十分之六的患者在眼科手術後15天內完全沒有炎症。Eyenovia 於 2023 年 8 月從臺塑製藥手中收購了 0.05% 的丙酸氯倍他索眼用混懸液的美國商業版權。預計0.05％的丙酸氯倍他索眼用混懸液最快將於今年夏天上市。
"Clobetasol propionate ophthalmic suspension 0.05% was developed to provide ophthalmologists and ocular surgery patients with a compelling, rapid, sustained and more convenient postoperative anti-inflammatory and pain relief solution. It is the first new ophthalmic steroid to enter the U.S. market in over 15 years, making it an exciting product for our physician network, and providing NovaBay with the opportunity to further leverage this channel," said Justin Hall, CEO of NovaBay. "Our physician-dispensed channel has become increasingly important in building our Avenova business. We have found that eyecare professionals carrying our products in their offices and recommending Avenova to their patients at the time of care delivers a halo effect by stimulating online product sales."
“0.05% 的丙酸氯倍他索眼用混懸液的開發旨在爲眼科醫生和眼科手術患者提供一種引人注目、快速、持續和更方便的術後抗炎和止痛解決方案。它是15年來第一種進入美國市場的新型眼科類固醇，使其成爲我們醫生網絡中令人興奮的產品，也爲NovaBay提供了進一步利用這一渠道的機會。” NovaBay首席執行官賈斯汀·霍爾說。“我們的醫生分配的渠道在建立我們的Avenova業務方面變得越來越重要。我們發現，眼部護理專業人員在辦公室攜帶我們的產品並在護理時向患者推薦Avenova會刺激在線產品銷售，從而產生光環效應。”
"NovaBay has a nationwide established network of thousands of eyecare professionals through its physician-dispensed channel, thereby presenting a ready-made opportunity to complement our established salesforce and accelerate the commercialization of this product," stated Michael Rowe, CEO of Eyenovia. "Although Avenova Antimicrobial Lid & Lash Solution has been on the market since 2015, there is considerable opportunity to generate professional awareness and grow sales. This co-promotion agreement reflects our shared commitment to bring scientifically developed, cutting-edge and high-quality ophthalmic products to physicians and the patients they treat."
Eyenovia首席執行官邁克爾·羅表示：“NovaBay通過其醫生分配的渠道在全國範圍內建立了由數千名眼科護理專業人員組成的網絡，從而爲補充我們現有的銷售隊伍和加速該產品的商業化提供了現成的機會。”“儘管Avenova抗菌眼皮和睫毛解決方案自2015年以來一直在市場上市，但仍有相當大的機會來提高專業知名度和增加銷售額。該共同推廣協議反映了我們的共同承諾，即爲醫生及其治療的患者提供科學開發、尖端和高質量的眼科產品。”
PLEASE GO TO CLOBETASOLBID.COM FOR IMPORTANT SAFETY INFORMATION for CLOBETASOL PROPRIONATE OPHTHALMIC SUSPENSION 0.05%
請前往 CLOBETASOLBID.COM 了解氯倍他索丙酸酯眼藥混懸液 0.05% 的重要安全信息
About Clobetasol Propionate Ophthalmic Suspension 0.05%
Clobetasol propionate ophthalmic suspension 0.05% demonstrated successful Phase 3 clinical results in resolving inflammation and pain following ocular surgery in a rapid and sustained manner. Adverse events were infrequent, with none occurring in over 2% of patients. Clobetasol propionate ophthalmic suspension 0.05% offers a convenient dosing regimen of one drop, twice daily for two weeks, whereas most other post-surgical eye drops are dosed up to four times each day.
關於丙酸氯倍他索眼用混懸液 0.05%
0.05% 的丙酸氯倍他索眼用混懸液在快速持續地緩解眼部手術後的炎症和疼痛方面取得了成功的3期臨床結果。不良事件很少發生，超過2％的患者沒有發生不良事件。0.05% 的丙酸氯倍他索眼藥混懸液提供了一種方便的給藥方案，每天兩次，持續兩週，而大多數其他術後滴眼液每天最多劑量四次。
About Avenova
Manufactured in the U.S., Avenova spray is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye yet is non-irritating and completely safe for regular use. A non-prescription version of Avenova is available directly to consumers through online distribution channels such as Amazon.com and Avenova.com.
關於 Avenova
Avenova 噴霧劑在美國製造，採用 NovaBay 專利、專有、穩定和純淨的次氯酸配製而成。臨床證明，它可以殺死多種細菌，有助於緩解細菌性乾眼症狀，但無刺激性，經常使用完全安全。非處方版的Avenova可通過亞馬遜和Avenova.com等在線分銷渠道直接向消費者提供。
About Eyenovia, Inc.
關於 Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery, which was approved by the FDA on March 4, 2024.
Eyenovia, Inc.（納斯達克股票代碼：EYEN）是一家處於商業階段的眼科製藥技術公司，正在開發基於其Optejet平台的微劑量陣列打印療法產品線。Eyenovia目前專注於治療散大的Mydcombi（託吡卡胺+去氧腎上腺素眼用噴霧劑）以及0.05％的用於減輕眼部手術後疼痛和炎症的丙酸氯倍他索眼藥混懸液的商業化，該懸浮液於2024年3月4日獲得美國食品藥品管理局的批准。
PLEASE GO TO MYDCOMBI.COM FOR IMPORTANT SAFETY INFORMATION for MYDCOMBI (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%
請前往 MYDCOMBI.COM 獲取 MYDCOMBI（託匹卡胺和鹽酸去氧腎上腺素眼用噴霧劑）1%/2.5% 的重要安全信息
Eyenovia is also advancing late-stage development of medications in the Optejet device for presbyopia (Apersure/MicroLine) and myopia progression (MicroPine, both partnered with Arctic Vision in China and South Korea).
Eyenovia還在推進Optejet設備中治療老花眼（Apersure/MicroLine）和近視進展（MicroPine，均與中國和韓國的北極願景合作）藥物的後期開發。
For more information, visit Eyenovia.com.
欲了解更多信息，請訪問Eyenovia.com。
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.
Eyenovia 企業信息幻燈片可在ir.eyenovia.com/活動和演示中找到。
譯文內容由第三人軟體翻譯。